Combination locoregional and systemic therapies in hepatocellular carcinoma

doi:10.1016/S2468-1253(24)00247-4

Review

. 2025 Apr;10(4):369-386.

doi: 10.1016/S2468-1253(24)00247-4. Epub 2025 Feb 21.

Combination locoregional and systemic therapies in hepatocellular carcinoma

Bin-Yan Zhong¹, Wenzhe Fan², Justin J Guan³, Zhenwei Peng⁴, Zhongzhi Jia⁵, Haojie Jin⁶, Zhi-Cheng Jin⁷, Jian-Jian Chen⁷, Hai-Dong Zhu⁷, Gao-Jun Teng⁸

Affiliations

¹ Center of Interventional Radiology and Vascular Surgery, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China; Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
² Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
³ Division of Interventional Radiology, Department of Radiology, Cleveland Clinic, Cleveland, OH, USA.
⁴ Department of Radiation Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
⁵ Department of Interventional and Vascular Surgery, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, China.
⁶ Shanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁷ Center of Interventional Radiology and Vascular Surgery, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
⁸ Center of Interventional Radiology and Vascular Surgery, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China. Electronic address: gjteng@seu.edu.cn.

PMID: 39993404
DOI: 10.1016/S2468-1253(24)00247-4

Review

Combination locoregional and systemic therapies in hepatocellular carcinoma

Bin-Yan Zhong et al. Lancet Gastroenterol Hepatol. 2025 Apr.

. 2025 Apr;10(4):369-386.

doi: 10.1016/S2468-1253(24)00247-4. Epub 2025 Feb 21.

Authors

Bin-Yan Zhong¹, Wenzhe Fan², Justin J Guan³, Zhenwei Peng⁴, Zhongzhi Jia⁵, Haojie Jin⁶, Zhi-Cheng Jin⁷, Jian-Jian Chen⁷, Hai-Dong Zhu⁷, Gao-Jun Teng⁸

Affiliations

¹ Center of Interventional Radiology and Vascular Surgery, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China; Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
² Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
³ Division of Interventional Radiology, Department of Radiology, Cleveland Clinic, Cleveland, OH, USA.
⁴ Department of Radiation Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
⁵ Department of Interventional and Vascular Surgery, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, China.
⁶ Shanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁷ Center of Interventional Radiology and Vascular Surgery, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
⁸ Center of Interventional Radiology and Vascular Surgery, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China. Electronic address: gjteng@seu.edu.cn.

PMID: 39993404
DOI: 10.1016/S2468-1253(24)00247-4

Abstract

Locoregional therapies play a fundamental role in the treatment of patients with early and intermediate and locally advanced hepatocellular carcinomas. With encouraging recent advances in immunotherapy-based systemic therapies, locoregional therapies are being both promoted and challenged by new systemic therapy options. Combined locoregional and systemic therapies might enhance treatment outcomes compared with either option alone. This Series paper summarises the existing data on locoregional and systemic therapies for hepatocellular carcinoma, and discusses evidence from studies investigating their combination with a focus on their synergistic efficacy and safety.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests We declare no competing interests.

Cited by

Efficacy and safety of D-TACE followed by D-RFA for unresectable large hepatocellular carcinoma.
Pang Q, Luo W, Chen S, Zhou H, Zhang R, Li Y, Zhao J, Yuan C, Wang G. Pang Q, et al. Front Oncol. 2025 Jul 28;15:1530951. doi: 10.3389/fonc.2025.1530951. eCollection 2025. Front Oncol. 2025. PMID: 40792272 Free PMC article.
Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Donafenib and Camrelizumab in the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Retrospective, Single-Arm Study.
Wu C, Fu Z, Pan L, Li J, Zhou Y, Sun R, Gou Y, Zhao Y, Wang Z, Qiu Y, Huang P. Wu C, et al. J Hepatocell Carcinoma. 2025 Jul 10;12:1353-1367. doi: 10.2147/JHC.S525454. eCollection 2025. J Hepatocell Carcinoma. 2025. PMID: 40661238 Free PMC article.
Sorafenib with or without co-interventions for hepatocellular carcinoma.
Chen S, Liu JP, Li X, Dang S, Li W. Chen S, et al. Cochrane Database Syst Rev. 2025 Jun 26;6(6):CD015851. doi: 10.1002/14651858.CD015851. Cochrane Database Syst Rev. 2025. PMID: 40568833 Free PMC article. Review.
Role of zinc finger protein 71 in hepatocellular carcinoma: Methodological concerns, clinical relevance, and future directions.
Krishnan A, Mukherjee D. Krishnan A, et al. World J Hepatol. 2025 Jun 27;17(6):106573. doi: 10.4254/wjh.v17.i6.106573. World J Hepatol. 2025. PMID: 40606925 Free PMC article.
Long-term trends and future projections of liver cancer burden in China from 1990 to 2030.
Zhan Z, Chen B, Huang R, Lin W, Lan S, Yao X, Huang S, Lin W, Xu S, Zhou S, Yu J, Wang X, Lin X, Guo Z. Zhan Z, et al. Sci Rep. 2025 Apr 16;15(1):13120. doi: 10.1038/s41598-025-96615-1. Sci Rep. 2025. PMID: 40240432 Free PMC article.

See all "Cited by" articles

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Combination locoregional and systemic therapies in hepatocellular carcinoma

Affiliations

Combination locoregional and systemic therapies in hepatocellular carcinoma

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Medical